Telix Pharmaceuticals share price jumps to record high on Nasdaq IPO launch

This radiopharmaceuticals company is expecting to pull in US$200m from the move.

| More on:
Businessman working on street in New York. Dressing in blue suit, a young guy with beard, sitting outside office building, looking down, reading, typing on laptop computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price has caught the eye of investors on Thursday.

In morning trade, the radiopharmaceuticals company's shares surged over 6% to a record high of $19.06.

Telix's shares have since pulled back but remain up slightly at the time of writing.

Why did the Telix Pharmaceuticals share price jump to a record high?

Investors were buying the company's shares this morning after it announced that it was following in the footsteps of Life360 Inc (ASX: 360) by launching an initial public offering (IPO) on Wall Street.

According to the release, Telix Pharmaceuticals will be listing American Depositary Shares (ADSs) on the Nasdaq Global Market, each representing one ordinary share in Telix. The target size of the offering is US$200 million in gross proceeds.

In addition, the company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs sold in the offering at the initial public offering price, less underwriting discounts and commissions.

Why is Telix joining the Nasdaq?

Telix Pharmaceuticals' chair, Kevin McCann, spoke a little about the company's proposed Nasdaq listing at its annual general meeting last month.

While he wasn't able to say too much at the time, McCann stated his belief that the move would be a good one for Telix and open the door to a number of opportunities and create long term value for shareholders. McCann stated:

Last Friday, 17 May 2024, we announced the public filing of our registration statement on Form-1 with the U.S. Securities and Exchange Commission (SEC) and confirmation of our intention to list on the Nasdaq Global Market. We are restricted by U.S. legal requirements on what we can say in respect of the potential U.S. listing at this stage.

But I can express our belief that this potential next step is fitting as we enter the next stage of our evolution. It enables Telix to better access the deep pool of specialist investors focused on biotechnology and radiopharmaceuticals in the U.S.

It is also our expectation that it will further increase recognition of the value of our therapeutic pipeline and raise visibility of Telix in the U.S. – and indeed globally. In turn, this will drive long-term value creation for shareholders.

The Telix Pharmaceuticals share price is now up 63% since this time last year and an even more impressive 1,600% over the last five years.

Motley Fool contributor James Mickleboro has positions in Life360 and Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Life360 and Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »

A person wrapped in warm clothing with head, eyes and face covered by a hat, glasses and a scarf is coated in a layer of snow and ice. representing Strike Energy's trading halt today
Healthcare Shares

Why is the Telix Pharmaceuticals share price frozen today?

Telix Pharmaceuticals shares won’t be moving today.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

3 ASX 300 healthcare stocks 'well positioned to outperform'

Wilsons thinks the healthcare sector could be about to outperform the broader market.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

CSL shares can 'absolutely' head to $500: ASX expert

This expert reckons it's foolish to bet against CSL...

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX biotech shares that could be the next Telix Pharmaceuticals

These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

Read more »